Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column.
via NYT > Business Day http://ift.tt/SbtyeA
via WordPress http://ift.tt/1kiRt5V
via All Business Is Good Business http://ift.tt/1nZHZjd
via WordPress http://ift.tt/1mOWtjM
0 comments:
Post a Comment